Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Recher

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL GroupCecile Bally, Jehane Fadlallah, Guy Leverger, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
American Journal of Hematology|May 14, 2022
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemiaBrian A Jonas, Andrew H Wei, Christian Recher, et al.
Cancer|April 8, 2015
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL groupThorsten Braun, Sophie Cereja, Sylvie Chevret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experienceEric Jourdan, Jean-Michel Boiron, Nicole Dastugue, et al.
The New England Journal of Medicine|September 15, 2007
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisArnaud Jaccard, Philippe Moreau, Veronique Leblond, et al.
Haematologica|February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapyThomas Pabst, Norbert Vey, Lionel Adès, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroupThomas Prébet, Nicolas Boissel, Sarah Reutenauer, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL GroupCecile Bally, Jehane Fadlallah, Guy Leverger, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
American Journal of Hematology|May 14, 2022
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemiaBrian A Jonas, Andrew H Wei, Christian Recher, et al.
Cancer|April 8, 2015
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL groupThorsten Braun, Sophie Cereja, Sylvie Chevret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experienceEric Jourdan, Jean-Michel Boiron, Nicole Dastugue, et al.
The New England Journal of Medicine|September 15, 2007
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisArnaud Jaccard, Philippe Moreau, Veronique Leblond, et al.
Haematologica|February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapyThomas Pabst, Norbert Vey, Lionel Adès, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroupThomas Prébet, Nicolas Boissel, Sarah Reutenauer, et al.
Pageof 14